In vitro antiplatelet activity of extract and its fractions of Paulownia Clone in Vitro 112 leaves.


Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
May 2021
Historique:
received: 20 11 2020
revised: 15 01 2021
accepted: 18 01 2021
pubmed: 10 2 2021
medline: 20 7 2021
entrez: 9 2 2021
Statut: ppublish

Résumé

Paulownia Clone in Vitro 112, also known as Oxytree is a hybrid of Paulownia elongata and Paulownia fortunei, developed under laboratory conditions. Its seeds are sterile, making it a noninvasive variety that can only be propagated in the laboratory. In China, species from the Paulownia genus (Paulowniaceae) are widely used in traditional medicine for the treatment of infectious diseases, such as gonorrhea and erysipelas. It has a broad spectrum of bioactivity, including neuroprotective, antioxidant, antibacterial, antiphlogistic, antiviral, and cytotoxic actions. However, the antiplatelet potential of Paulownia Clone in Vitro 112 has not yet been described. The aim of our study was thus to examine the effect of an extract and four fractions from leaves of Paulownia Clone in Vitro 112 on various parameters of platelet activation in an in vitro model. Composition of the investigated extract and fractions was determined by UHPLC-UV-MS. The following parameters of platelet activation were investigated: nonenzymatic lipid peroxidation in resting platelets; enzymatic lipid peroxidation (AA metabolism) in platelets activated by thrombin; superoxide anion (O Verbascoside a phenylethnanoid glycoside, was the main secondary metabolite of the extract from leaves of oxytree (constituting approximately 45 % of all compounds). There were also iridoids, such as catalpol, aucubin, and 7-hydroxytomentoside, as well as flavonoids, such as luteolin and apigenin glycosides. Moreover, the extract had stronger antiplatelet properties than the fractions. For example, the extract at 10 μg/mL inhibited five parameters of platelet activation. Our results show that Paulownia Clone in Vitro 112 leaves are a new valuable source of compounds with antiplatelet potential.

Sections du résumé

BACKGROUND BACKGROUND
Paulownia Clone in Vitro 112, also known as Oxytree is a hybrid of Paulownia elongata and Paulownia fortunei, developed under laboratory conditions. Its seeds are sterile, making it a noninvasive variety that can only be propagated in the laboratory. In China, species from the Paulownia genus (Paulowniaceae) are widely used in traditional medicine for the treatment of infectious diseases, such as gonorrhea and erysipelas. It has a broad spectrum of bioactivity, including neuroprotective, antioxidant, antibacterial, antiphlogistic, antiviral, and cytotoxic actions. However, the antiplatelet potential of Paulownia Clone in Vitro 112 has not yet been described.
STUDY DESIGN METHODS
The aim of our study was thus to examine the effect of an extract and four fractions from leaves of Paulownia Clone in Vitro 112 on various parameters of platelet activation in an in vitro model.
METHODS METHODS
Composition of the investigated extract and fractions was determined by UHPLC-UV-MS. The following parameters of platelet activation were investigated: nonenzymatic lipid peroxidation in resting platelets; enzymatic lipid peroxidation (AA metabolism) in platelets activated by thrombin; superoxide anion (O
RESULTS RESULTS
Verbascoside a phenylethnanoid glycoside, was the main secondary metabolite of the extract from leaves of oxytree (constituting approximately 45 % of all compounds). There were also iridoids, such as catalpol, aucubin, and 7-hydroxytomentoside, as well as flavonoids, such as luteolin and apigenin glycosides. Moreover, the extract had stronger antiplatelet properties than the fractions. For example, the extract at 10 μg/mL inhibited five parameters of platelet activation.
CONCLUSIONS CONCLUSIONS
Our results show that Paulownia Clone in Vitro 112 leaves are a new valuable source of compounds with antiplatelet potential.

Identifiants

pubmed: 33561640
pii: S0753-3322(21)00086-X
doi: 10.1016/j.biopha.2021.111301
pii:
doi:

Substances chimiques

Glucosides 0
Phenols 0
Plant Extracts 0
Platelet Aggregation Inhibitors 0
acteoside 3TGX09BD5B

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111301

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Weronika Adach (W)

University of Łódź, Department of General Biochemistry, Faculty of Biology and Environmental Protection, 90-236, Łódź, Poland.

Jerzy Żuchowski (J)

Department of Biochemistry, Institute of Soil Science and Plant Cultivation, State Research Institute, 24-100, Puławy, Poland.

Barbara Moniuszko-Szajwaj (B)

Department of Biochemistry, Institute of Soil Science and Plant Cultivation, State Research Institute, 24-100, Puławy, Poland.

Małgorzata Szumacher-Strabel (M)

Department of Animal Nutrition, Poznań University of Life Sciences, Wołyńska 33, 60-637, Poznań, Poland.

Anna Stochmal (A)

Department of Biochemistry, Institute of Soil Science and Plant Cultivation, State Research Institute, 24-100, Puławy, Poland.

Beata Olas (B)

University of Łódź, Department of General Biochemistry, Faculty of Biology and Environmental Protection, 90-236, Łódź, Poland. Electronic address: beata.olas@biol.uni.lodz.pl.

Adam Cieslak (A)

Department of Animal Nutrition, Poznań University of Life Sciences, Wołyńska 33, 60-637, Poznań, Poland. Electronic address: adam.cieslak@up.poznan.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH